Real-world outcomes of elderly patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) treated with chimeric antigen receptor T-cell (CAR-T) therapy.
Lindsey Fitzgerald(Huntsman Cancer Institute), Boyu Hu(University of Utah), Caron A. Jacobson(Broad Institute), Loretta J. Nastoupil(The University of Texas MD Anderson Cancer Center), Janet Spradley(University of Colorado Denver), Anna Saucier(Dana-Farber Cancer Institute), Adam S. Kittai(The Ohio State University Wexner Medical Center), Nathan Denlinger(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Manali Kamdar(University of Colorado Cancer Center), Alexandra Waller(The University of Texas MD Anderson Cancer Center), Jonathan Chipman(University of Utah)
Cited by 19
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782
Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas
|Nature Medicine|2020|593
Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update
|Journal of Clinical Oncology|2018|574
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523